Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systemic Chemotherapy For Psoriasis: A National Survey

Systemic Chemotherapy For Psoriasis: A National Survey Abstract • A questionnaire that was mailed to 510 randomly selected dermatologists in the United States surveyed their use of three systemic chemotherapeutic agents for the treatment of psoriasis during the two-year period of 1973 to 1974. Methotrexate was used by 52% of the surveyed dermatologists, while hydroxyurea and azaribine were used by 10% and 2%, respectively. Seventy-five percent of the dermatologists who used methotrexate treated ten or fewer psoriatic patients with this drug. Multiple dose therapy with methotrexate divided over a period of 36 hours each week was the preferred schedule of 66% of the dermatologists. Liver biopsy specimens and creatinine clearance tests were obtained for only 17% and 35% of patients, respectively, prior to initiating methotrexate therapy. The estimated number of dermatologisttreated psoriatics nationwide receiving methotrexate is 25,000. (Arch Dermatol 112:977-981, 1976) References 1. Van Scott EJ, Auerbach R, Weinstein GD: Parenteral methotrexate in psoriasis . Arch Dermatol 84:550-556, 1964.Crossref 2. Roenigk HH Jr, Bergfeld WF, Curtis GH: Methotrexate for psoriasis in weekly oral doses . Arch Dermatol 99:86-93, 1969.Crossref 3. Weinstein GD, Frost P: Methotrexate for psoriasis: A new therapeutic schedule . Arch Dermatol 103:33-38, 1971.Crossref 4. Edmundson WF, Guy WB: Treatment of psoriasis with folic acid antagonists . Arch Dermatol 78:200-203, 1958.Crossref 5. Leavell VW Jr, Yarbro JW: Hydroxyurea: A new treatment for psoriasis . Arch Dermatol 102:144-150, 1970.Crossref 6. Moschella SL, Greenwald MA: Psoriasis with hydroxyurea: An 18-month study of 60 patients . Arch Dermatol 107:363-368, 1973.Crossref 7. Milstein HG, Cornell RC, Stoughton RB: Azaribine in the treatment of psoriasis: A low dose, double-blind evaluation . Arch Dermatol 108:43-47, 1973.Crossref 8. Volger WR, Olansky S: A double-blind study of azaribine in the treatment of psoriasis . Ann Intern Med 73:951-956, 1970.Crossref 9. Jones EL, Epinette WW, Hackney VC, et al: Treatment of psoriasis with oral mycophenolic acid , abstracted. J Invest Dermatol 60:246, 1973. 10. Roenigk HH, Maibach HI, Weinstein GD: Use of methotrexate in psoriasis, editorial . Arch Dermatol 105:363-365, 1972.Crossref 11. Roenigk HH, Maibach HI, Weinstein GD: Methotrexate therapy for psoriasis: Guideline revisions . Arch Dermatol 108:35, 1973.Crossref 12. Weinstein GD, Roenigk H, Maibach H, et al: Psoriasis-liver-methotrexate interactions . Arch Dermatol 108:36-42, 1973.Crossref 13. Rees RB, Bennett JH, Maibach HI, et al: Methotrexate for psoriasis . Arch Dermatol 95:2-11, 1967.Crossref 14. Roenigk HH Jr: Methotrexate: Where are we today? , in Farber EM, Cox AC (eds): Psoriasis, Proceedings of the International Symposium, Stanford University, 1971 . Stanford, Calif, Stanford University Press, 1971, pp 465-474. 15. Gullen WH, Garrison GE: Factors influencing physician's response to mailed questionnaires . Health Serv Rep 88:510-514, 1973.Crossref 16. Schor S: Questionnaire studies . JAMA 223:1497, 1973.Crossref 17. Levine A, Roizen P, Rozé P, et al: A mathematical method for analysing questionnaires . Bull WHO 47:87-97, 1972. 18. Halprin KM, Fukui K, Ohkawara A: Blood levels of methotrexate and the treatment of psoriasis . Arch Dermatol 103:243-249, 1971.Crossref 19. Dahl MGC, Baker H: Drug reactions: VI. Methotrexate and the liver . Br J Dermatol 81:465-7, 1971. 20. McDonald CI, Bertino IR: Parenteral methotrexate for psoriasis . Lancet 1:864, 1968.Crossref 21. Menghini G: One-second biopsy of the liver: Problems of its clinical application . N Engl J Med 283:582-585, 1970.Crossref 22. Bailin PL, Tindall JP, Roenigk HH, et al: Is methotrexate therapy for psoriasis carcinogenic?: A modified retrospective-prospective analysis . JAMA 232:359-362, 1975.Crossref 23. Liegler D, Henderson D, Hahn MA, et al: Renal clearance and in vivo protein binding of methotrexate in man and changes associated with salicylate administration , abstracted. Proc Am Assoc Cancer Res 8:41, 1967. 24. Dixon RL, Henderson ES, Rall DP: Plasma protein binding of methotrexate and its displacement by various drugs . Fed Proc 24:454, 1965. 25. Baker H: Methotrexate in psoriasis . Lancet 1:205, 1968.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Dermatology American Medical Association

Systemic Chemotherapy For Psoriasis: A National Survey

Loading next page...
 
/lp/american-medical-association/systemic-chemotherapy-for-psoriasis-a-national-survey-nZzfBWAidq
Publisher
American Medical Association
Copyright
Copyright © 1976 American Medical Association. All Rights Reserved.
ISSN
0003-987X
eISSN
1538-3652
DOI
10.1001/archderm.1976.01630310039008
Publisher site
See Article on Publisher Site

Abstract

Abstract • A questionnaire that was mailed to 510 randomly selected dermatologists in the United States surveyed their use of three systemic chemotherapeutic agents for the treatment of psoriasis during the two-year period of 1973 to 1974. Methotrexate was used by 52% of the surveyed dermatologists, while hydroxyurea and azaribine were used by 10% and 2%, respectively. Seventy-five percent of the dermatologists who used methotrexate treated ten or fewer psoriatic patients with this drug. Multiple dose therapy with methotrexate divided over a period of 36 hours each week was the preferred schedule of 66% of the dermatologists. Liver biopsy specimens and creatinine clearance tests were obtained for only 17% and 35% of patients, respectively, prior to initiating methotrexate therapy. The estimated number of dermatologisttreated psoriatics nationwide receiving methotrexate is 25,000. (Arch Dermatol 112:977-981, 1976) References 1. Van Scott EJ, Auerbach R, Weinstein GD: Parenteral methotrexate in psoriasis . Arch Dermatol 84:550-556, 1964.Crossref 2. Roenigk HH Jr, Bergfeld WF, Curtis GH: Methotrexate for psoriasis in weekly oral doses . Arch Dermatol 99:86-93, 1969.Crossref 3. Weinstein GD, Frost P: Methotrexate for psoriasis: A new therapeutic schedule . Arch Dermatol 103:33-38, 1971.Crossref 4. Edmundson WF, Guy WB: Treatment of psoriasis with folic acid antagonists . Arch Dermatol 78:200-203, 1958.Crossref 5. Leavell VW Jr, Yarbro JW: Hydroxyurea: A new treatment for psoriasis . Arch Dermatol 102:144-150, 1970.Crossref 6. Moschella SL, Greenwald MA: Psoriasis with hydroxyurea: An 18-month study of 60 patients . Arch Dermatol 107:363-368, 1973.Crossref 7. Milstein HG, Cornell RC, Stoughton RB: Azaribine in the treatment of psoriasis: A low dose, double-blind evaluation . Arch Dermatol 108:43-47, 1973.Crossref 8. Volger WR, Olansky S: A double-blind study of azaribine in the treatment of psoriasis . Ann Intern Med 73:951-956, 1970.Crossref 9. Jones EL, Epinette WW, Hackney VC, et al: Treatment of psoriasis with oral mycophenolic acid , abstracted. J Invest Dermatol 60:246, 1973. 10. Roenigk HH, Maibach HI, Weinstein GD: Use of methotrexate in psoriasis, editorial . Arch Dermatol 105:363-365, 1972.Crossref 11. Roenigk HH, Maibach HI, Weinstein GD: Methotrexate therapy for psoriasis: Guideline revisions . Arch Dermatol 108:35, 1973.Crossref 12. Weinstein GD, Roenigk H, Maibach H, et al: Psoriasis-liver-methotrexate interactions . Arch Dermatol 108:36-42, 1973.Crossref 13. Rees RB, Bennett JH, Maibach HI, et al: Methotrexate for psoriasis . Arch Dermatol 95:2-11, 1967.Crossref 14. Roenigk HH Jr: Methotrexate: Where are we today? , in Farber EM, Cox AC (eds): Psoriasis, Proceedings of the International Symposium, Stanford University, 1971 . Stanford, Calif, Stanford University Press, 1971, pp 465-474. 15. Gullen WH, Garrison GE: Factors influencing physician's response to mailed questionnaires . Health Serv Rep 88:510-514, 1973.Crossref 16. Schor S: Questionnaire studies . JAMA 223:1497, 1973.Crossref 17. Levine A, Roizen P, Rozé P, et al: A mathematical method for analysing questionnaires . Bull WHO 47:87-97, 1972. 18. Halprin KM, Fukui K, Ohkawara A: Blood levels of methotrexate and the treatment of psoriasis . Arch Dermatol 103:243-249, 1971.Crossref 19. Dahl MGC, Baker H: Drug reactions: VI. Methotrexate and the liver . Br J Dermatol 81:465-7, 1971. 20. McDonald CI, Bertino IR: Parenteral methotrexate for psoriasis . Lancet 1:864, 1968.Crossref 21. Menghini G: One-second biopsy of the liver: Problems of its clinical application . N Engl J Med 283:582-585, 1970.Crossref 22. Bailin PL, Tindall JP, Roenigk HH, et al: Is methotrexate therapy for psoriasis carcinogenic?: A modified retrospective-prospective analysis . JAMA 232:359-362, 1975.Crossref 23. Liegler D, Henderson D, Hahn MA, et al: Renal clearance and in vivo protein binding of methotrexate in man and changes associated with salicylate administration , abstracted. Proc Am Assoc Cancer Res 8:41, 1967. 24. Dixon RL, Henderson ES, Rall DP: Plasma protein binding of methotrexate and its displacement by various drugs . Fed Proc 24:454, 1965. 25. Baker H: Methotrexate in psoriasis . Lancet 1:205, 1968.Crossref

Journal

Archives of DermatologyAmerican Medical Association

Published: Jul 1, 1976

References